IgA nephropathy (IgAN), IgA vasculitis (IgAV), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), and minimal change disease (MCD) account for the majority of idiopathic glomerulo-nephropathies (GN). These disorders involve immune system dysregulation and have a complex genetic architecture. Currently, there are no adequately powered blood transcriptomic datasets coupled to genetic data from patients with GN that can delineate disease-context specific genetic effects on the blood immune cell transcriptome. We performed whole genome sequencing coupled with bulk blood transcriptome sequencing on 1,822 participants from the CureGN study, a prospective cohort of participants with a kidney biopsy diagnosis of primary GN. We generated disease-context specific transcriptome-wide maps of gene expression QTL (eQTL), splicing QTL (sQTL), and double strand RNA-editing QTL (edQTL) for FSGS (N=447), IgAN (N=403), IgAV (N=123), MCD (N=408), and MN (N=441), as well as cross-disease maps for all 1,822 participants. Our QTL mapping identified 16,068 eGenes, 4,644 sGenes and 4,611 edQTLs with an FDR<0.05 in at least one GN type. Approximately 5-10% of the QTL signals were unique to a specific GN type, while ~90% were shared between at least two conditions. Colocalization analysis demonstrated that ~80% of shared eGenes between traits also shared the same causal variants, whereas ~2% had distinct causal variants, suggesting context-specific regulatory effects. Cross-phenotype QTL mapping uncovered 6,466 eGenes, 2,705 sGenes and 5,321 edQTLs not previously detected in GTEx. Age, eGFR, and proteinuria-interaction QTL analyses identified hundreds of loci modified by age or disease severity. Lastly, integrative analyses with GWAS nominated new candidate genes for each of the five GN types under study. In summary, we generated comprehensive maps of GN-context-specific genetic effects on the blood transcriptome, providing a powerful new resource for integrative gene discovery studies of primary GN.

Membranous nephropathy (MN), an autoimmune glomerulopathy driven by podocyte antigens, is a leading cause of end-stage renal disease (ESRD). However, its pathogenic mechanisms remain incompletely understood. This knowledge gap results in significant physical and psychological burdens for patients worldwide and poses substantial challenges for clinical management. Current conventional treatments for MN are often associated with significant side effects and may not yield satisfactory outcomes. Therefore, the development of more efficacious and better-tolerated therapeutic strategies for MN is imperative. Given these clinical challenges, Traditional Chinese Botanical Medicine (CHMs), with their multi-component and multi-target characteristics, have emerged as a promising alternative or complementary therapeutic approach for MN. This review aims to summarize the evidence on the mechanisms and clinical efficacy of CHMs and their active metabolites in treating MN, drawing from findings reported in animal experiments, clinical trials, systematic reviews, and meta-analyses. It seeks to elucidate the potential advantages of CHMs in MN management and to provide a reference for future research in this field. Study design and methods: For this review, the following major academic research databases were consulted: PubMed, ResearchGate, Science Direct, and Web of Science. "Glomerulonephritis, Membranous [MeSH Terms] OR Extramembranous Glomerulopathy [Text Word] OR Membranous Glomerulonephropathy [Text word] OR Membranous Nephropathy [Text word] OR Idiopathic Membranous Glomerulonephritis [Text word]OR Glomerulonephritides, Idiopathic Membranous. [Text word])," "(Medicine, Chinese Traditional [MeSH Terms] OR Medicine, Chinese Traditional [Text Word] OR Medicine, Chinese Traditional [Text word] OR Tongue Diagnosis, Traditional [Text word] OR Traditional Tongue Assessment [Text word]," "Drugs, Chinese Herbal [MeSH Terms] OR Chinese Drugs, Plant [Text Word] OR Chinese Herbal Drugs [Text word] OR Plant Extracts, Chinese [Text word] OR Chinese Plant Extracts [Text word]," "mechanism," "Meta-analysis," "systematic review," "RCT," "botanical drug" and their combinations were the keywords to search the relevant literature. Data were collected from 2019 to 2025.

Integrating coding and regulatory variation into unified, interpretable representations remains a challenge in functional genomics. Current approaches either focus on common variants or analyze individual variants in isolation, missing the cumulative, cell-type-specific impact of both coding and noncoding variants on each gene. We present Volaria, a computational framework that integrates coding and regulatory genetic variation into unified, gene-centered representations for disease outcome prediction from whole-genome sequencing. Volaria leverages deep learning models to capture variant effects on cell-type-specific gene expression and integrates them with AI-predicted exonic variant pathogenicity to produce representations that capture the cumulative effect of genome-wide rare and common variation. Applied to whole genomes of individuals with rare glomerular diseases, Volaria predicts individual outcomes directly from germline sequence, demonstrating that structured, cell-type-aware representations capture predictive signals beyond population-based polygenic risk scores and unstructured representations. Importantly, the framework identifies context-specific biological mechanisms, providing interpretability that can be aligned with clinical measurements. By encoding genome-wide variation into compact and biologically grounded representations, Volaria provides a scalable foundation for genome interpretation and individualized outcome modeling from germline sequence, complementing phenotypic and clinical information in the future integrative frameworks.

From 2015 to 2024, inclusion body hepatitis (IBH) was diagnosed in a total of 346 chicken necropsy cases submitted to the California Animal Health and Food Safety (CAHFS) laboratory system. The majority of cases (68%; 237/346) originated from a single commercial broiler company with a high density of poultry premises within the California Central Valley region. Reported mortality varied between 0.5% and 4.8% per day, and morbidity ranged between 5% and 10%. Clinical signs observed in affected flocks included depression, reluctance to move, ruffled feathers, greenish diarrhea, and, occasionally, icterus of skin and adipose tissue. Typical histopathological lesions included extensive hepatic necrosis, multifocal pancreatic necrosis, gizzard erosions, and glomerulonephropathy. Intranuclear inclusions were identified, mainly within degenerating hepatocytes, followed by pancreatic acinar cells, glandular epithelium of proventriculus and gizzard, and enterocytes of the small intestines and renal endothelium. Diagnosis was based on microscopic changes characteristic of IBH and a positive conventional PCR targeting the hexon gene of fowl adenovirus (FAdV) on liver tissue pools. Sequence analysis was performed on 41 selected FAdV-positive samples from diagnostic cases. The majority of FAdV PCR-positive samples aligned with FAdV-8b (16/41). However, FAdV-7 (14/41), FAdV-4 (7/41), and FAdV-11 (4/41) were also detected from IBH cases. Disease management was successfully achieved by the administration of an autogenous vaccine to breeders, at 11 and 18 wk of age, to confer maternal antibody protection to the broiler progeny.

Image features that characterize tubules from digitized kidney biopsies may offer insight into disease prognosis as novel biomarkers. For each subject, we can construct a matrix whose entries are a common set of image features (e.g., area, orientation, eccentricity) that are measured for each tubule from that subject's biopsy. Previous scalar-on-matrix regression approaches which can predict scalar outcomes using image feature matrices cannot handle varying numbers of tubules across subjects. We propose the CLUstering Structured laSSO (CLUSSO), a novel scalar-on-matrix regression technique that allows for unbalanced numbers of tubules, to predict scalar outcomes from the image feature matrices. Through classifying tubules into one of two different clusters, CLUSSO averages and weights tubular feature values within-subject and within-cluster to create balanced feature matrices that can then be used with structured lasso regression. We develop the theoretical large tubule sample properties for the error bounds of the feature coefficient estimates. Simulation study results indicate that CLUSSO often achieves a lower false positive rate and higher true positive rate for identifying the image features which truly affect outcomes relative to a naive method that averages feature values across all tubules. Additionally, we find that CLUSSO has lower bias and can predict outcomes with a competitive accuracy to the naïve approach. Finally, we applied CLUSSO to tubular image features from kidney biopsies of glomerular disease subjects from the Nephrotic Syndrome Study Network (NEPTUNE) to predict kidney function and used subjects from the Cure Glomerulonephropathy (CureGN) study as an external validation set.

IgA nephropathy (IgAN) is one of the most prevalent glomerulonephropathies and commonly leads to kidney failure. The recurrence of IgAN following transplantation remains a significant concern. Currently, detecting IgAN recurrence requires a kidney biopsy, highlighting the need for non-invasive biomarkers such as donor-derived cell-free DNA (dd-cfDNA) to aid in early detection. This prospective pilot study aims to evaluate dd-cfDNA as a non-invasive biomarker for detecting IgAN recurrence post-kidney transplantation. Specifically, the study seeks to compare %dd-cfDNA levels in transplanted patients with and without IgAN recurrence and correlate these levels with other kidney function parameters. A total of 32 patients with histologically confirmed IgAN were enrolled, including those with documented IgAN recurrence post-transplantation and those without recurrence. Plasma samples were collected and processed using the AlloSeq cfDNA kit to quantify relative %dd-cfDNA levels. Kidney function parameters, including estimated glomerular filtration rate (eGFR) and proteinuria, were also assessed. The study found no significant difference in %dd-cfDNA levels between transplanted patients with IgAN recurrence and those without recurrence (median 0.37% [IQR 0.28%-3.53%] vs. median 0.42% [IQR 0.15%-0.84%], p = 0.67). Also, %dd-cfDNA (AUC = 0.57 [95% CI 0.28-0.85], p = 0.64) failed to effectively discriminate IgAN recurrence compared to traditional kidney function parameters such as proteinuria (AUC = 0.96 [95% CI 0.87-1.00], p = 0.002) and eGFR (AUC = 0.74 [95% CI 0.47-1.00], p = 0.09). Relative (%) dd-cfDNA alone may not be a robust biomarker for detecting IgAN recurrence post-transplantation. While proteinuria proved a more effective indicator in this study, kidney biopsy remains the gold standard for definitive diagnosis. These findings highlight the challenges of using %dd-cfDNA as a standalone diagnostic tool for monitoring IgAN recurrence post-transplantation. Future research should explore larger patient cohorts and longitudinal assessments to refine the utility of dd-cfDNA and investigate potential combination strategies with other biomarkers.